Celsion Granted SFDA Approval for China Cancer Trial
October 16, 2009 at 02:17 AM EDT
Celsion Corporation has received SFDA approval to include China sites in its global Phase III clinical trial of a new liver cancer therapy, ThermoDox. ThermoDox is a liposomal encapsulation of doxorubicin, a commonly used chemotherapy drug; the formulation is designed to release its active ingredient when heated. Celsion said China’s acceptance of the trial is very significant due to the size of China’s market. China is home to over half of the world’s HCC patients. More details... Stock Symbol: (NSDQ: CLSN)